Abstract 192P
Background
Studies of apatinib monotherapy suggest that ARAE (proteinuria, hand-foot syndrome [HFS] and hypertension) may predict clinical outcomes in patients with AGC; however, this phenomenon has not been reported in patients receiving apatinib + chemotherapy. We evaluated the potential association between ARAE and efficacy outcomes of apatinib +chemotherapy for AGC.
Methods
We reviewed two prospective trials of patients treated with apatinib + chemotherapy (POF or paclitaxel alone), a phase II study (ESMO-ASIA 2018) and a phase I study (ESMO 2022). POF was paclitaxel 135 mg/m2 over 3 h followed by leucovorin 400 mg/m2 and oxaliplatin 85 mg/m2 over 2 h; then 5-FU 2,400 mg/m2 continuous infusion over 46 h. Drugs were started days 1 and 15 of each 28-day cycle. Paclitaxel alone was 80 mg/m2 days 1, 8, and 15 of every 28-day cycle. Presence of any ARAE in the first 4 weeks of therapy was assessed and the primary outcome was overall survival (OS). OS was estimated using Kaplan-Meier with the log-rank test. Hazard ratios (HRs) were calculated by univariate and multivariate Cox proportional regression models.
Results
The number of participants was 43 (POF, n=41; paclitaxel alone, n=2). In the first 4 weeks of treatment, 22 (51.2%) had any grade proteinuria, 13 (30.0%) had any grade HFS, and 14 (32.6%) had any grade hypertension. The presence of proteinuria or HFS was associated with prolonged median OS ([months] proteinuria 5.93 vs. 19.10; HR 0.40, 95% CI 0.20-0.79; P=0.0065; HFS 8.92 vs. 22.57 ; HR 0.48, 95% CI 0.23-0.98; P=0.04) and progression-free survival ([PFS] proteinuria 3.50 vs. 9.60 ; HR 0.46, 95% CI 0.23-0.91; P=0.022; HFS 6.40 vs. 10.67 ; HR 0.54, 95% confidence interval (CI) 0.27-1.07; P=0.073 ). 24 (55.8%) patients had one (any grade) proteinuria or HFS in the first 4 weeks, which was associated with prolonged median OS (6.77 vs. 16.35 ; HR 0.47, 95% CI 0.24-0.93; P=0.031) and PFS (4.20 vs. 8.75; HR 0.55, 95% CI 0.28-1.08; P=0.080).
Conclusions
Antiangiogenesis-related proteinuria and HFS may be biomarkers to predict antitumor efficacy of apatinib + chemotherapy in AGC. Future prospective studies are needed to validate findings.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
122P - Distinct transcriptomic immune profiling and clinicopathological features of cribriform morphology in colorectal adenocarcinomas
Presenter: Abdelhakim Khellaf
Session: Poster Display
Resources:
Abstract
123P - Spatial molecular profiling identifies FGF20 upregulation on cancer-associated fibroblast and FGFR2-PI3K/Akt activation in tumor cells of sporadic early-onset colon cancer
Presenter: Dave Hoon
Session: Poster Display
Resources:
Abstract
124P - Characteristics, prognosis and therapeutic effects of non-V600 BRAF mutated colorectal cancer
Presenter: Lalida Arsa
Session: Poster Display
Resources:
Abstract
125P - Final results of APOLLON-11 and SOYUZ-APOLLON study: Multicentre prospective observational post-authorization study of bevacizumab biosimilar in patients with metastatic colorectal cancer in real-world practice
Presenter: Alexey Tryakin
Session: Poster Display
Resources:
Abstract
126P - From tumor height (TH) to tumor regression grade (TRG) in locally advanced rectal cancers (LARC) during total neadjuvant therapy (TNT): A retrospective analysis
Presenter: Valeria Pusceddu
Session: Poster Display
Resources:
Abstract
127P - A meta-analysis of efficacy and safety from head-to-head first-line (1L) trials of epidermal growth factor receptor inhibitors (EGFRIs) versus bevacizumab in combination with chemotherapy (CT) doublets in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC) by sidedness
Presenter: Takayuki Yoshino
Session: Poster Display
Resources:
Abstract
128TiP - A phase II study of cadonilimab + FOLFOXIRI and bevacizumab as initial therapy for unresectable proficient mismatch repair/microsatellite stable (pMMR/MSS) metastatic colorectal cancer (mCRC)
Presenter: Rongbo Lin
Session: Poster Display
Resources:
Abstract
140P - Prevalence of claudin-18 isoform 2 (CLDN18.2) positivity in locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mg/GEJ) adenocarcinoma in patients (pts) in the Asia region: Phase III SPOTLIGHT and GLOW studies
Presenter: Hoo Hwoei Fen Soo
Session: Poster Display
Resources:
Abstract
141P - Early phase trials outcomes in refractory upper GI cancers: A 10-year analysis from the SCRI UK phase I unit
Presenter: Antonella Cammarota
Session: Poster Display
Resources:
Abstract
142P - The survival impact of the addition of durvalumab to cisplatin/gemcitabine in advanced biliary tract cancer: A real-world, retrospective, multicentric study
Presenter: Silvia Foti
Session: Poster Display
Resources:
Abstract